tbuckley/cabot-search huggingface dataset:
miR-17-92/p38α Dysregulation Enhances Wnt Signaling and Selects Lgr6+ Cancer Stem-like Cells during Lung Adenocarcinoma Progression
Authors: Anna Guinot, Feride Oeztuerk-Winder, Juan-Jose Ventura
Journal: Cancer Research (2016)

Defining the molecular and cellular roots of lung cancer relapse after initial treatment remains an imperative to improve survival. Here we report that the lung stem cell marker Lgr6 becomes enriched in non-small cell lung cancer (NSCLC) cells during malignant progression. Lgr6(+) NSCLC cells displayed self-renewal and differentiation properties along with a higher tumorigenic potential. Mechanistic investigations suggested that a defective repression of the miR-17-92 gene cluster was responsible for evolution of a selection for outgrowth of Lgr6(+) NSCLC cells. High levels of expression of miR-19 family members were found to target and downregulate levels of p38α kinase, providing a specific survival signal for Lgr6(+) cells as mediated by increased Wnt/ß-catenin activity. Our results identify a specific stem-like cell population in NSCLC with increased malignant potential, the elucidation of which may enable earlier prognosis and possibly the development of more effective targeted treatments. Cancer Res; 76(13); 4012-22. ©2016 AACR.
Does age influence the intrinsic biology of breast cancer?
Authors: Tomo Osako, Steven McKinney, Damian Yap, Gulisa Turashvili, Samuel Aparicio
Journal: Journal of Clinical Oncology (2015)

11044 Background: The incidence of breast cancer and its molecular subtype are age-related. Patient age may be associated with breast cancer biology through subtype-determining genetic factors (e.g. BRCA1 germline mutation) or aging of the tissue of origin (e.g. telomere shortening or epigenetic modifications in breast epithelium). EZH2 catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3), an epigenetic change playing a role in breast cancer development and progression. We investigated if biomarkers including EZH2 and H3K27me3 display age-associated expression in breast cancer and if non-malignant breast epithelium reflects any age-dependent associations. Methods: Two independent sets of breast cancer tissues (n = 3,464 and n = 1,537) and a set of normal breast tissues of non-cancer patients who underwent reduction mammoplasty surgery (n = 537) were used to construct tissue microarrays for protein expression analysis using immunohistochemistry (42, 19 and 12 markers analyzed, respectively). A set of breast cancer tumour samples (n = 1,992) was assayed for global gene expression analysis using Illumina HT-12 gene chips. The associations of biomarker expression with patient age were statistically investigated. Results: In breast cancer,EZH2 protein and mRNA expression decreased and H3K27me3 marks increased with age at diagnosis. Gene expression analysis showed that more than 10% of genes (2,708 of about 25,000 genes) showed significant age-associated expression, and gene set enrichment analysis showed that these were enriched in 34 pathways. In non-malignant breast epithelium, EZH2, H3K27me3, ER, Ki67, EGFR and FOXA1 showed age-associated trends, which were similar to the trends seen in breast cancer. Conclusions: Patient age may influence the biology of breast cancer, and age-associated gene expression data leads us to hypothesize a mechanism involving histone modification by EZH2. Understanding the age-associated biology offers hope for age-specific preventive and therapeutic options.
A magnetic resonance imaging study of autism: normal fourth ventricle size and absence of pathology
Authors: H J Garber, E R Ritvo, L C Chiu, V J Griswold, A Kashanian, B J Freeman, W H Oldendorf
Journal: American Journal of Psychiatry (1989)

Magnetic resonance imaging did not diagnose neuropathology in 15 autistic patients. Measurements of the midsagittal area and volume of the fourth ventricle did not differ between these patients and matched control subjects.
Toward Meaning
Authors: B D Feldstein
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Platelet Depletion Causes Rapid But Transient Activation Of Mouse Bone Marrow Long-Term Hematopoietic Stem Cells To Participate In Stress Thrombopoiesis
Authors: Lijian Shao, Di Hou, Wei Feng, Jianhui Chang, Jerry Ware, Martin Hauer-Jensen, Tao Cheng, Daohong Zhou
Journal: Blood (2013)
Significance of Fibrinogen and the D-Dimer Level for Predicting the Risk of Fatal Bleeding in Patients with Acute Promyelocytic Leukemia.
Authors: Dae-Young Kim, Je-Hwan Lee, Jung-Hee Lee, Sung-nam Lim, Sung-Doo Kim, Yunsuk Choi, Kyung-Hwa Lee, Joo Youn Kim, Young-Shin Lee, Young-Ah Kang, Miee Seol, Yeon-Joo Lee, Kyoo-Hyung Lee
Journal: Blood (2009)
European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity
Authors: Andrew Bush, Angelo Barbato, Annick Clement, Steve Cunningham, Jacques de Blic, Carlee Gilbert, Lutz Goldbeck, Nural Kiper, Nicolaus Schwerk, Matthias Griese
Journal: European Respiratory Journal (2016)

The European charter for idiopathic pulmonary fibrosis is a welcome document [1], highlighting unmet needs in patients which will inform policy makers across Europe. However, it is sad that an important opportunity to involve children with interstitial lung diseases (ILDs) has been missed. There is a current pan-European paediatric ILD consortium [2] which could have been used to access these children and families. Our own work also highlighted similar themes [3]: diagnostic delay, the need for improved holistic care and written information, and also interestingly highlighted a previously undescribed issue, the high prevalence of feeding disorders in these children. So the European Charter, excellent as it is, sadly represents a lost opportunity to represent the needs of children with rare lung diseases to health commissioners. Children with ILD should also have been included in the IPF European Charter <http://ow.ly/ZBfA0>
FDG PET/MRI Imaging of an Angiosarcoma in a Popliteal Aneurysm and Tibial Head After Popliteal Graft
Authors: Thomas Bader, Klaus Strobel, Michèle Egger-Sigg, Joachim Diebold, Martin Beck
Journal: Clinical Nuclear Medicine (2016)

Angiosarcomas are rare aggressive neoplasms with a wide variety of anatomic locations, one third of them presenting multifocal. Molecular imaging with PET/CT and PET/MR plays an emerging role in staging sarcomas. This case demonstrates the value of PET/MR imaging of an angiosarcoma with involvement of the tibial head and a popliteal aneurysm with histopathologic correlation.
Self-portrait
Authors: Carrie A. Butt
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FDG uptake in chronic superior vena cava thrombus on positron emission tomographic imaging.
Authors: EUGENE LIN, ROBERT QUAIFE
Journal: Clinical Nuclear Medicine (2001)

From the Division of Nuclear Medicine, University of Colorado Health Sciences Center, Denver, Colorado Received for publication April 19, 2000. Accepted July 24, 2000. Reprint requests: Eugene C. Lin, Department of Radiology, University Hospital, Box A-034, 4,200 East Ninth Avenue, Denver, Colorado 80262. E-mail: [email protected]
Abstract 21108: Impaired HDL Metabolism and Remodeling is Associated with More Vulnerable Coronary Plaque Phenotype as Assessed by Quantitative Contrast-Enhanced CT Coronary Angiography
Authors: Sarah Rinehart, Gustavo Vazquez, Parag Joshi, Eric Krivitsky, Laura Murrieta, Zhen Qian, Bela Asztalos, Ernst Schaefer, Szilard Voros
Journal: Circulation (2010)

Background:. HDL particles are protective against atherosclerosis. Adequate maturation of smaller HDL particles to larger, cholesterol-rich HDL particles is critical for reverse cholesterol transpo...
Margaret McCartney: Optional disclosure of payments is pointless
Authors: Margaret McCartney
Journal: BMJ (2016)

Naked, luscious transparency! Hurrah! The Association of the British Pharmaceutical Industry (ABPI) is about to reveal, ladies and gentlemen, the pounds and pence that the industry has paid to healthcare professionals, along with their names. The obfuscatory kit of amalgamated payments and anonymity is coming off.

But this is all being done with the recipients’ consent, so the entire charade has all the thrust of a dead jellyfish. Doctors can opt out, meaning that a key opinion leader can earn hundreds of thousands of pounds while influencing patients, colleagues, formularies, and policies—and we won’t know. Owing, we are told, to data protection issues (ie, consent is required for sharing), transparency is not …
P0956 : MIR-22 deficiency exacerbates systemic and hepatic metabolic disorders associated with diet-induced obesity in mice
Authors: A.-S. Berthomieu, D. Portius, D. Abegg, P. Rantakari, F.-P. Zhang, M. Poutanen, D. Picard, S. Nef, A. Adibekian, M. Foti
Journal: Journal of Hepatology (2015)
Brexit threatens stability of medical science workforce, researchers have warned
Authors: Tom Moberly
Journal: BMJ (2016)

The United Kingdom’s exit from the European Union will threaten the stability of the medical science workforce by undermining projects funded by the EU and could make the UK a less attractive place for EU scientists to work, researchers have warned.

Rustam Al-Shahi Salman, a professor of clinical neurology at the University of Edinburgh, told the online publication Vox , “Brexit will immediately destabilize our ongoing European Union-funded multi-center studies.”1 He said that the future of projects being established or seeking …
Family Assessment of Quality of Care in the Last Month of Life
Authors: Stacy M. Fischer, David Bekelman, F. Amos Bailey
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Time for a Model List of Essential Diagnostics
Authors: Lee F. Schroeder, Jeannette Guarner, Ali Elbireer, Philip E. Castle, Timothy K. Amukele
Journal: New England Journal of Medicine (2016)

Many diagnostic tests are required for fulfilling the health care needs of populations. A Model List of Essential Diagnostics could play a global health policy role similar to that of the Model List of Essential Medicines maintained by the World Health Organization.
Soundings: Fire down below
Authors: James Owen Drife
Journal: BMJ (2002)

Someone somewhere must have been the first to compare reorganising the NHS with rearranging the deckchairs on the Titanic. The joke does not bear analysis—the health service is not about to capsize—but “rearranging the deckchairs” entered the language because it catches the real feeling in the engine room about activities on the bridge.

The only people who go up and down the ladder between the two are doctors. A few of us spend part of the week in London on the medical equivalent of the promenade deck and part of it back home working in the galley.

Or rather, this week, not working. I am writing in January and elective surgery in our hospital has been cancelled, as it was last year and the year before that and the year . . .

Below deck, your reaction is fury. You are the person who saw the patients and shared their pain and anxiety. You are the person who will see them when they are finally admitted. Your fury is only increased by knowing that they will not blame you or anyone else for the failures of the NHS.

Above deck, you are all urbanity. You nibble a custard cream, comment on the second draft of a discussion document, and check your diary for dates for the next meeting.

If yesterday's anger intrudes into your conversation you feel foolish. Your colleagues smile and advise you not to let it get to you. After a while you think they are right.

Your upper deck friends are talented and committed people. They may not feel raw rage when the service breaks down but they do want to improve things. The problem is that the higher people are in the NHS ship, the less is the fire in their belly. And on the bridge are the politicians, cold as ice and ignorant about everything except politics.

It may be mythology but I like to think that the NHS was brought into being by combining Beveridge's cool brain and Bevan's hot blood. According to his biographer, Michael Foot, Aneurin Bevan was “a man of passion and compassion.” Those are exactly the qualities missing from the politicians who are steering the ship today.

Those, and knowledge about life below deck.
<i>DRD4</i>, Income, and Children’s Food Choices
Authors: Vivian Yeo, Alison Poulton, Anu Ashokan
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization
Authors: Marta C. Nunes, Clare L. Cutland, Stephanie Jones, Andrea Hugo, Richard Madimabe, Eric A. F. Simões, Adriana Weinberg, Shabir A. Madhi
Journal: JAMA Pediatrics (2016)

Influenza immunization of women during pregnancy protects the young infants against influenza illness. The duration of this protection remains unclear.To evaluate the duration of infant protection conferred by maternal immunization and its association with transplacental antibody transfer.Infants born to women who participated in a randomized, double-blind, placebo-controlled clinical trial in 2011 and 2012 on the safety, immunogenicity, and efficacy of trivalent inactivated influenza vaccine (IIV3) during pregnancy were followed up during the first 6 months of life for polymerase chain reaction (PCR)-confirmed influenza illness. In a secondary analysis of a subset of infants, hemagglutination inhibition (HAI) antibodies were measured. The study was performed at a single center in South Africa. The secondary analysis was performed in October 2014.Maternal immunization for influenza.The vaccine's efficacy against PCR-confirmed influenza illness and the percentage of infants with HAI titers of 1:40 or more by age group.There were 1026 infants (47.2% female) born to IIV3 recipients and 1023 infants (47.3% female) born to placebo recipients who were included in the analysis of the vaccine's efficacy. The vaccine's efficacy against PCR-confirmed influenza illness was highest among infants 8 weeks of age or younger at 85.6% (95% CI, 38.3%-98.4%) and decreased with increasing age to 25.5% (95% CI, -67.9% to 67.8%) among infants 8 to 16 weeks of age and to 30.3% (95% CI, -154.9% to 82.6%) among infants 16 to 24 weeks of age. Similarly, in the IIV3 group, the percentage of infants with HAI titers of 1:40 or more to the influenza vaccine strains decreased from more than 56% in the first week of life to less than 40% at 16 weeks of age and less than 10.0% at 24 weeks of age.Maternal immunization conferred protection against infection in the infants for a limited period during early life. The lack of protection beyond 8 weeks of age correlated with a decrease in maternally derived antibodies.clinicaltrials.gov Identifier: NCT01306669.
Evaluation of hypersensitivity reactions to oxaliplatin in gastrointestinal malignancies.
Authors: Kelly Markey, Tyra Gatewood, Tiffany Valone, Jonathan R. Strosberg
Journal: Journal of Clinical Oncology (2016)

709 Background: Oxaliplatin is an important component of therapy for multiple gastrointestinal cancers. The incidence of hypersensitivity reaction (HSR) to oxaliplatin is approximately 10%, and about 3% are serious in nature (Grade 3 or 4). Data on management of hypersensitivity reactions is limited to small case series, with scarce information on the success rates of rechallenging patients who have previously reacted. Methods: We conducted a retrospective review of patients who had a documented hypersensitivity (HSR) to oxaliplatin utilizing our internal adverse event reporting system from January 1, 2007 until December 31, 2012. Results: 44 patients met inclusion criteria for this study. The majority had a grade 1 or 2 reaction (n = 36 or 81.82%). Seven patients had a grade 3 reaction and one patient experienced a grade 4 reaction. 29 patients were rechallenged with oxaliplatin during subsequent courses. Infusion durations were extended in 79% of cases, and additional premedications were administered in 90%. Two patients were treated with a desensitization protocol, which consisted of serial dilutions of oxaliplatin (given over approximately 8 hours) with a two-stage premedication regimen. With these measures, seventeen of the twenty-nine patients (66%) were able to receive 3 or more additional infusions, thirteen (45%) received 5 or more additional infusions, and 4 (14%) we able to receive 10 or more additional infusions. Conclusions: Our review of hypersensitivity reactions to oxaliplatin demonstrates that the majority of patients experience mild (Grade 1 or 2) reactions and are able to be successfully rechallenged in subsequent courses with modifications in the infusion rate and premedications. The use of these treatment strategies may prevent premature discontinuation of an important backbone drug for the treatment of gastrointestinal malignancies.
Real-world treatment patterns and health care resource utilization (HRU) among patients with chronic lymphocytic leukemia (CLL) by regimen.
Authors: Brad Schenkel, Lorie Ellis, Stephanie Korrer, Stacey DaCosta Byfield
Journal: Journal of Clinical Oncology (2016)

15 Background: Few studies examine HRU of CLL, the most common hematologic malignancy in adults. This study describes HRU by the most common regimens among CLL patients (pts). Methods: A retrospective study using a large, national U.S. claims database from 1/2007-10/2013 was conducted. Adult CLL pts (≥2 claims for CLL) with ≥1 claim for systemic anticancer therapy (SACT) were identified; first SACT claim date was the index date. Pts had to have a CLL diagnosis ≤3 months (m) prior to the index date and be continuously enrolled (CE) in the health plan for 24m pre- and ≥6m post-index date. Pregnant pts and those with SACT in the pre-index period were excluded. A line of therapy (LOT) started with the first SACT; regimens included all agents received in the first 60 days. LOTs ended at the earliest of, start of a new drug, ≥60-day gap in receipt of initial regimen drugs, death or CE end. All-cause HRU was examined by regimen. Results: There were 946 CLL pts identified. Mean age was 68 years, 63% were male, and by insurance type, 41% were Medicare Advantage vs. 59% commercially insured. During the first LOT, 96% and 78% of pts had ≥1 office or hospital outpatient visit with mean per patient per month (PPPM) visits of 4.3 (standard deviation, SD = 2.8) and 2.2 (SD = 2.8), respectively. 31% and 25% had ≥1 ER visit or inpatient stay with mean PPPM visits of 0.2 (SD = 0.4) and 0.1 (SD = 0.3), respectively. Mean PPPM count of inpatient stay days was 1.4 (SD = 8.0). In first LOT, the top 3 regimens accounted for 56% of pts: FCR: fludarabine, cyclophosphamide, rituximab (19%); R: rituximab (19%); BR: bendamustine, rituximab (18%). During the study period, 318 pts (34%) started a second LOT. The top 3 LOT2 regimens accounted for 52% of pts: R (30%); BR (14%); chlorambucil (8%). Conclusions: HRU of CLL pts varied by initial regimen received. Future studies should examine influences of regimen choice and whether regimen choice is associated with differences in outcomes. [Table: see text]